CN104606194A - Pde4的双环杂芳基抑制剂 - Google Patents

Pde4的双环杂芳基抑制剂 Download PDF

Info

Publication number
CN104606194A
CN104606194A CN201410768897.2A CN201410768897A CN104606194A CN 104606194 A CN104606194 A CN 104606194A CN 201410768897 A CN201410768897 A CN 201410768897A CN 104606194 A CN104606194 A CN 104606194A
Authority
CN
China
Prior art keywords
nc3c
ccc2c
amino
alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410768897.2A
Other languages
English (en)
Chinese (zh)
Inventor
S·P·戈瓦克
A·K·施奥
S·A·诺布勒
D·J·托马斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN104606194A publication Critical patent/CN104606194A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201410768897.2A 2006-07-07 2007-07-06 Pde4的双环杂芳基抑制剂 Pending CN104606194A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81950906P 2006-07-07 2006-07-07
US60/819,509 2006-07-07
US88682507P 2007-01-26 2007-01-26
US60/886,825 2007-01-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800330480A Division CN101528228A (zh) 2006-07-07 2007-07-06 Pde4的双环杂芳基抑制剂

Publications (1)

Publication Number Publication Date
CN104606194A true CN104606194A (zh) 2015-05-13

Family

ID=38739981

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410768897.2A Pending CN104606194A (zh) 2006-07-07 2007-07-06 Pde4的双环杂芳基抑制剂

Country Status (11)

Country Link
US (5) US8080563B2 (https=)
EP (1) EP2037924A2 (https=)
JP (2) JP5280357B2 (https=)
KR (2) KR20090109527A (https=)
CN (1) CN104606194A (https=)
AU (1) AU2007269070B2 (https=)
BR (1) BRPI0713253A2 (https=)
CA (1) CA2657093A1 (https=)
CO (1) CO6190532A2 (https=)
MX (1) MX2009000148A (https=)
WO (3) WO2008006052A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490739A (zh) * 2019-01-23 2021-10-08 通路治疗公司 通过磷酸二酯酶4(pde4)抑制治疗癫痫的方法

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EP1483283A4 (en) 2002-03-13 2007-04-11 Signum Biosciences Inc MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE
ES2335498T3 (es) 2003-03-10 2010-03-29 Nycomed Gmbh Nuevo proceso para la preparacion de reflumilast.
CA2601777A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
CA2657093A1 (en) 2006-07-07 2008-01-10 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
US8138205B2 (en) * 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
AU2009239430B2 (en) 2008-04-21 2015-01-22 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
CN101353338B (zh) * 2008-07-10 2011-05-04 上海交通大学 糖胺改性的水溶性香豆素酮衍生物及其制备方法
CN102548536A (zh) * 2009-10-01 2012-07-04 爱尔康研究有限公司 奥洛他定组合物及其用途
CA2796826A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bifunctional quinoline derivatives
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
US20130116279A1 (en) * 2011-11-07 2013-05-09 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of pde4
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
MD20170011A2 (ro) 2014-08-06 2017-08-31 Pfizer Inc. Compuşi imidazopiridazinici
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
MX383072B (es) 2015-12-24 2025-03-13 Univ California Reguladores del cftr y métodos para su uso
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CN106916104B (zh) * 2017-02-28 2019-08-27 牡丹江医学院 用于治疗结肠炎的药物
AU2018307730B9 (en) 2017-07-26 2024-02-15 Hg&H Pharmaceuticals (Pty) Ltd Mesembrenol and/or mesembranol for prophylaxis and treatment of patients suffering from epilepsy and associated diseases
JP2020531511A (ja) 2017-08-24 2020-11-05 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 眼球用医薬組成物
US20220371990A1 (en) * 2019-09-08 2022-11-24 Hadasit Medical Research Services And Developmect Ltd. Anti-fibrotic compounds and use thereof
IL300628A (en) * 2020-09-10 2023-04-01 Vanda Pharmaceuticals Inc Methods for the treatment of cyclic diseases or conditions-PDE IV

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032449A2 (en) * 1997-12-19 1999-07-01 Zambon Group S.P.A. Benzazine derivatives as phosphodiesterase 4 inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US542104A (en) * 1895-07-02 Nut-sheller
AU639529B2 (en) 1987-03-04 1993-07-29 Higuchi, Yoshinari Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
ES2059828T3 (es) * 1988-01-15 1994-11-16 Abbott Lab Un procedimiento para la preparacion de un compuesto.
EP0549729B1 (en) * 1990-09-07 1997-12-17 Schering Corporation Antiviral compounds and antihypertensive compounds
US5430153A (en) 1991-04-03 1995-07-04 Korea Research Institute Of Chemical Technology 2-quinolinone derivatives
AU5626494A (en) 1992-11-27 1994-06-22 Byk Nederland Bv Nitroxy compounds with pharmaceutical properties
FR2703683B1 (fr) 1993-04-08 1995-07-07 Seractec Dérivés d'aminocoumarines hydrophobes, et leur utilisation comme substrats d'enzymes protéolytiques ou pour la préparation de tels substrats.
FR2711992A1 (fr) 1993-11-03 1995-05-12 Lipha Nouveaux dérivé hétérocycliques, procédé de préparation et composition pharmaceutique les contenant.
DE4337906A1 (de) 1993-11-08 1995-05-11 Cassella Ag Verwendung von Cumarinderivaten
US5563280A (en) * 1994-07-25 1996-10-08 American Cyanamid Co. 4-Phenoxycoumarins as herbicidal agents
EP0861242B1 (en) * 1995-10-13 2001-05-30 Aventis CropScience UK Limited Heterocyclic fungicides
US20040081959A9 (en) * 1999-12-08 2004-04-29 Epoch Biosciences, Inc. Fluorescent quenching detection reagents and methods
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
US6436971B2 (en) * 2000-02-09 2002-08-20 Smithkline Beecham Corporation Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection
DE10021256A1 (de) * 2000-04-20 2001-10-31 Forschungsverbund Berlin Ev Neue, photolabile Cumarinylmethylester von cyclischen Nucleotiden, Verfahren zu deren Herstellung und ihre Verwendung
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
DE60115069T2 (de) 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
US6740666B2 (en) * 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
JP2002371078A (ja) 2001-06-12 2002-12-26 Sankyo Co Ltd キノリン誘導体及びキノロン誘導体
JP2003146972A (ja) * 2001-11-14 2003-05-21 Teikoku Hormone Mfg Co Ltd カルボスチリル誘導体
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US7148253B2 (en) * 2002-05-14 2006-12-12 Xtl Biopharmaceuticals Ltd. 4-thio coumarins
EP1504000A4 (en) 2002-05-14 2006-08-23 Vivoquest Inc 4-THIO COUMARINES
WO2004011446A1 (en) * 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
CN1506359A (zh) * 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
ITMI20022739A1 (it) * 2002-12-23 2004-06-24 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4.
MXPA06002876A (es) * 2003-09-15 2006-06-05 Signal Pharm Llc Compuestos de benzopiranona, composiciones de los mismos y metodos de tratamiento que los utilizan.
EP1718306A2 (en) 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
CA2565599C (en) * 2004-05-18 2012-07-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
ATE474833T1 (de) 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
NL1028569C2 (nl) 2005-03-18 2006-09-20 Rademaker Holding B V Toepassing van een coumarine-groep omvattende derivaten voor de bereiding van een antiviraal middel, alsmede kattenvoer.
US8048889B2 (en) * 2005-03-29 2011-11-01 Xtl Biopharmaceuticals Ltd. 3,4-disubstituted coumarin and quinolone compounds
DK1928457T3 (da) 2005-09-30 2013-02-04 Pulmagen Therapeutics Asthma Ltd Quinoliner og deres terapeutiske anvendelse
US8138205B2 (en) * 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
CA2657093A1 (en) 2006-07-07 2008-01-10 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
US20130116279A1 (en) * 2011-11-07 2013-05-09 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of pde4

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032449A2 (en) * 1997-12-19 1999-07-01 Zambon Group S.P.A. Benzazine derivatives as phosphodiesterase 4 inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BESSONOVA, ET AL.: "7-isopentenyloxy-γ-fagarine from haplophyllum perforatum", 《 CHEMISTRY OF NATURAL COMPOUNDS》 *
E.K. DOBRONRAVOVA, ET AL.: "Mechanism of the reduction of the alkaloids of haplophyllum at a droppingd mercury electrode", 《CHEMISTRY OF NATURAL COMPOUNDS》 *
O"DONNELL, F. ET AL.: "A study of the analytical behaviour of selected synthetic and naturally occurring quinolines using electrospray ionization ion trap mass spectrometry, liquid chromatography and gas chromatography and the construction of an appropriate database for quinolin", 《ANALYTICA CHIMICA ACTA》 *
T OHTA, Y MORI: "Furoquinolines. VI. Establishment of the linear tricyclic structures for dictamnine and skimmianine", 《PHARMACEUTICAL BULLETIN》 *
V. V. PLATONOV, ET AL.: "Genetic Relationship of Organic Bases of the Quinoline and Isoquinoline Series from Lignite Semicoking Tars with the Initial Biological Material", 《RUSSIAN JOURNAL OF APPLIED CHEMISTRY》 *
VETRIVEL NADARAJ, ET AL.: "Microwave-assisted synthesis of quinoline alkaloids: 4-Methoxy-1-methyl-2-quinolinone and its analogs", 《ARKIVOC》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490739A (zh) * 2019-01-23 2021-10-08 通路治疗公司 通过磷酸二酯酶4(pde4)抑制治疗癫痫的方法

Also Published As

Publication number Publication date
CO6190532A2 (es) 2010-08-19
EP2037924A2 (en) 2009-03-25
JP2009542815A (ja) 2009-12-03
WO2008006050A3 (en) 2008-06-26
WO2008006052A2 (en) 2008-01-10
WO2008006051A3 (en) 2008-06-26
US20100022586A1 (en) 2010-01-28
US9078887B2 (en) 2015-07-14
BRPI0713253A2 (pt) 2012-10-30
MX2009000148A (es) 2009-10-26
US7745646B2 (en) 2010-06-29
KR20090109527A (ko) 2009-10-20
US8258154B2 (en) 2012-09-04
US20090291950A1 (en) 2009-11-26
WO2008006051A2 (en) 2008-01-10
AU2007269070B2 (en) 2013-03-21
CA2657093A1 (en) 2008-01-10
US20080027112A1 (en) 2008-01-31
US8080563B2 (en) 2011-12-20
JP5280357B2 (ja) 2013-09-04
KR20150004441A (ko) 2015-01-12
JP5705269B2 (ja) 2015-04-22
JP2013177421A (ja) 2013-09-09
US20130178498A1 (en) 2013-07-11
WO2008006050A2 (en) 2008-01-10
WO2008006052A3 (en) 2008-11-20
US20080027099A1 (en) 2008-01-31
AU2007269070A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
JP7579402B2 (ja) 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物
CN104606194A (zh) Pde4的双环杂芳基抑制剂
EP3551610B1 (en) Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
JP7601788B2 (ja) チロシンキナーゼの複素環式阻害剤
BR112015009168B1 (pt) Composto de fórmula estrutural xi ou um sal do mesmo, uso de um composto e composição farmacêutica
US8138205B2 (en) Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
US20130116279A1 (en) Bicyclic heteroaryl inhibitors of pde4
JP2022553273A (ja) 疾患の治療のための二重ロイシンジッパー（ｄｌｋ）キナーゼのビシクロ［１．１．１］ペンタン阻害剤
EP4221709B1 (en) Imidazopiperazine inhibitors of transcription activating proteins
WO2018213777A1 (en) Heterocyclic inhibitors of kdm5 for the treatment of disease
CN101528228A (zh) Pde4的双环杂芳基抑制剂
HK1176056A (en) Bicyclic heteroaryl inhibitors of pde4
HK40016460A (en) Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
HK40016460B (en) Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150513

WD01 Invention patent application deemed withdrawn after publication